Newsletter 47/2026
LAST WEEK TODAY!
A summary of what was published on ProstateWarriors.com during the past week
|
|
Hello fellow warriors! Here we are, more good news, more trials for us.
Stay strong and fight on!
As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.
Clinical Research
- Phase 3 Trial: TALAPRO-2 Exploratory Biomarker Analysis
An exploratory analysis of the Phase 3 TALAPRO-2 trial published in The Lancet Oncology established that circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) dynamics strongly correlate with radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC). Evaluating 805 patients treated with talazoparib plus enzalutamide versus enzalutamide alone, the study showed an 84% concordance between tissue and ctDNA testing for homologous recombination repair (HRR) gene alterations, which rose to 89% when the blood tumor DNA fraction reached ≥1%. Patients with undetectable baseline ctDNA achieved significantly longer median rPFS compared to those with detectable ctDNA. Furthermore, clearing ctDNA by week 9 extended median rPFS to 25.9 months with combination therapy (vs. 10.8 months for persistent positivity), while CTC clearance (reduction from ≥5 to ≤4 cells/7.5 mL) by week 9 yielded a median rPFS of 22.1 months versus 5.5 months in non-responders.
- Phase 1/2 Trial: Five-Year Outcomes of the CROP Trial
Mature results from the prospective Phase 1/2 CROP trial reported encouraging long-term outcomes in 89 patients with oligometastatic hormone-sensitive prostate cancer treated with stereotactic body radiotherapy (SBRT) to all metastatic sites alongside 12 months of intermittent androgen deprivation therapy (ADT). At a median follow-up of 74.7 months, the 5-year overall survival reached 78.2%, with 22.8% of patients progressing to castration-resistant disease. Crucially, 39.3% of patients remained alive off ADT at their final assessment, supported by an 82.9% 3-year testosterone recovery rate and a median PSA nadir of 0.03 ng/mL.
- Phase 1/2 Trial: TREGCHECK 103 Immunotherapy Combination
The open-label, single-arm Phase 1/2 TREGCHECK 103 trial is investigating a novel combination immunotherapy combining tagmokitug (CHS-114) and pasritamigin approximately 12 patients with mCRPC. Pasritamig functions as a bispecific antibody that simultaneously engages KLK2 on prostate cancer cells and CD3 on T cells to direct cellular immune attacks. Tagmokitug complements this by targeting CCR8to selectively deplete regulatory T cells (Tregs) in the tumor microenvironment, thereby reducing local immune suppression.
- Phase 1/2 Trial: ARGATE-001 Evaluation of EIK1006
The U.S. FDA cleared an Investigational New Drug application for ARGATE-001, an upcoming first-in-human Phase 1/2 trial evaluating EIK1006, a next-generation androgen receptor (AR) antagonist, in patients with advanced metastatic prostate cancer. EIK1006 is engineered to bind the AR ligand-binding domain and prevent receptor translocation into the cell nucleus, blocking downstream oncogenic gene activation. Preclinical evaluations demonstrate that EIK1006 maintains activity against both wild-type AR and key resistance-associated AR mutations, offering a potential strategy for tumors that have progressed despite prior ARPI therapies such as enzalutamide, apalutamide, or darolutamide.
- Phase 1 Trial: Penetrium for Overcoming ARPI Resistance
An ongoing Phase 1 trial at Seoul National University Hospital is evaluating Penetrium (CP-PCA07), an experimental niclosamide-based agent designed to target tumor microenvironmental “pseudo-resistance” in mCRPC. By modifying physical and extracellular matrix barriers generated by cancer-associated fibroblasts, Penetrium aims to enhance drug delivery and sensitivity to existing ARPI treatments. Initial clinical observations from two patients treated with 600 mg daily Penetrium alongside enzalutamide demonstrated consecutive PSA declines and CT-confirmed lesion shrinkage in an abiraterone-resistant patient, as well as rapid PSA declines in a patient with prior enzalutamide resistance.
Preclinical Research & Reviews
- Met-Score 45-Gene Signature for Predicting Metastatic Risk
A retrospective genomic study published in the Journal of Translational Medicine introduced Met-Score, a 45-gene expression signature(comprising 27 upregulated and 18 downregulated genes) designed to predict which localized prostate cancers are likely to metastasize. Analyzed across 1,000 patients in six discovery cohorts, Met-Score demonstrated robust predictive accuracy in independent validation cohorts. Met-Score remained independently predictive of metastasis-free survival after adjusting for Gleason grade and improved risk discrimination among patients with Gleason 7 disease.
- HDAC6 Inhibition Restores Docetaxel Sensitivity
A preclinical study published in Frontiers in Pharmacology demonstrated that inhibiting the enzyme HDAC6 can restore docetaxel sensitivity in docetaxel-resistant castration-resistant prostate cancer cell lines. Utilizing resistant DU145 and 22Rv1 cell lines, researchers identified an experimental selective HDAC6 inhibitor, compound 9b, which increased tubulin acetylation, disrupted cell division, reduced cell migration, and acted synergistically with docetaxel to induce cell death. The study also revealed that HDAC6 blockade suppresses the MYC oncogene, providing direct evidence that HDAC6 contributes functionally to chemotherapy resistance.
And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.
If this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
Have a great weekend!
Max

Leave a Reply
Want to join the discussion?Feel free to contribute!